Safety of intravenous iron formulations: facts and folklore.

作者: Iain C Macdougall , Michael Auerbach

DOI: 10.2450/2014.0094-14

关键词:

摘要: It is unlikely that anyone reading this review was not taught intravenous (IV) iron dangerous. While early preparations were associated with an unacceptably high rate of serious adverse events, most notably anaphylactic shock, newer formulations carbohydrate shells which bind the elemental more tightly, allowing for a much slower release, are very safer toxicity being marginal to absent in prospective trials. The perception risk fueled by misinterpretation and misinformation clinical nature minor infusion reactions1, inappropriate use premedication diphenhydramine2 inferences made about relative safety available using spontaneous event reporting systems, methodologies proscribed regulatory agencies3,4. In article we published evidence on different formulations, highlight errors interpretation intervention when reactions occur, posit paradigm maximising underutilised therapeutic tool.

参考文章(42)
SIDNEY MARCHASIN, RALPH O. WALLERSTEIN, THE TREATMENT OF IRON-DEFICIENCY ANEMIA WITH INTRAVENOUS IRON DEXTRAN. Blood. ,vol. 23, pp. 354- 358 ,(1964) , 10.1182/BLOOD.V23.3.354.354
Manuel Muñoz, Susana Gómez-Ramírez, Jorge Cuenca, José Antonio García-Erce, Daniel Iglesias-Aparicio, Sami Haman-Alcober, Daniel Ariza, Enrique Naveira, Very‐short‐term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients Transfusion. ,vol. 54, pp. 289- 299 ,(2013) , 10.1111/TRF.12195
David Tovbin, Dalia Mazor, Marina Vorobiov, Cidio Chaimovitz, Naomi Meyerstein, Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. American Journal of Kidney Diseases. ,vol. 40, pp. 1005- 1012 ,(2002) , 10.1053/AJKD.2002.36334
Daniel W. Coyne, Franklin N. Adkinson, Allen R. Nissenson, Steven Fishbane, Rajiv Agarwal, Joseph W. Eschbach, Beckie Michael, Vaughn Folkert, Daniel Batlle, J. Richard Trout, Naomi Dahl, Pamela Myirski, Jur Strobos, David G. Warnock, Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients Kidney International. ,vol. 63, pp. 217- 224 ,(2003) , 10.1046/J.1523-1755.2003.00703.X
I. McLean Baird, D.A. Podmore, Intramuscular iron therapy in iron-deficiency anaemia. The Lancet. ,vol. 264, pp. 942- 946 ,(1954) , 10.1016/S0140-6736(54)92555-6
Roger D. Hamstra, Intravenous Iron Dextran in Clinical Medicine JAMA: The Journal of the American Medical Association. ,vol. 243, pp. 1726- 1731 ,(1980) , 10.1001/JAMA.1980.03300430028018
Gerald Faich, Jur Strobos, Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. American Journal of Kidney Diseases. ,vol. 33, pp. 464- 470 ,(1999) , 10.1016/S0272-6386(99)70183-6
Michael Auerbach, Robert C. Kane, Caution in making inferences from FDA's Adverse Event Reporting System. American Journal of Health-system Pharmacy. ,vol. 69, pp. 922- 923 ,(2012) , 10.2146/AJHP120138
Donald S. Silverberg, Adrian Iaina, Gary Peer, Eliezer Kaplan, Bat Ami Levi, Naama Frank, Shoshana Steinbruch, Miriam Blum, Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis American Journal of Kidney Diseases. ,vol. 27, pp. 234- 238 ,(1996) , 10.1016/S0272-6386(96)90546-6
Diane K. Wysowski, Lynette Swartz, B. Vicky Borders-Hemphill, Margie R. Goulding, Catherine Dormitzer, Use of parenteral iron products and serious anaphylactic-type reactions. American Journal of Hematology. ,vol. 85, pp. 650- 654 ,(2010) , 10.1002/AJH.21794